Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias

J. Kappelmayer, Attila Kiss, Éva Karászi, Anikó Veszprémi, János Jakó, C. Kiss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Immunophenotyping is considered to be less valuable in the diagnosis of acute myeloid leukaemias (AML) compared with acute lymphoid leukaemias. Here, we present data on the use of quantitative flow cytometry (QFC) of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and three-colour immunophenotyping including CD162 staining in the identification of myeloid precursors in AML. Analysis of normal peripheral blood (n = 20) and normal bone marrow (n = 5) samples and on 20 samples from de novo M1, M2, M4 and M5 AML patients demonstrated that PSGL-1 is differentially expressed on various mature and immature leucocyte subsets. It was found by QFC that neutrophils expressed 26500 ± 4500 and monocytes 47200 ± 9900 copies of PSGL-1 on their surface, whereas AML blasts from M1 and M2 AML patients expressed significantly less PSGL-1 (12 000 ± 5300) than mature neutrophils (P <0.001). In M4 and M5 leukaemias, however, the amount of PSGL-1 on monocytic precursors is displayed in a fairly broad range that is not significantly different from that of mature monocytes (P = 0.084). Using three-colour immunophenotyping PSGL-1-dim staining was co-expressed with CD7 and C34 positivity and PSGL-1 staining intensity on immature myeloid cells paralleled with CD45 expression. This would imply a differential expression of PSGL-1 during myeloid haematopoietic development and suggests that quantification of surface PSGL-1 may aid in differentiating myeloblasts from monoblasts by immunophenotyping in different AML subsets.

Original languageEnglish
Pages (from-to)903-909
Number of pages7
JournalBritish Journal of Haematology
Volume115
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Acute Myeloid Leukemia
Immunophenotyping
Staining and Labeling
Monocytes
Flow Cytometry
Neutrophils
Color
Monocyte-Macrophage Precursor Cells
Leukemia, Myelomonocytic, Acute
Leukemia, Monocytic, Acute
Granulocyte Precursor Cells
P-selectin ligand protein
Myeloid Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Leukocytes
Bone Marrow

Keywords

  • Monoblast
  • Myeloblast
  • PSGL-1
  • Quantitative flow cytometry

ASJC Scopus subject areas

  • Hematology

Cite this

Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias. / Kappelmayer, J.; Kiss, Attila; Karászi, Éva; Veszprémi, Anikó; Jakó, János; Kiss, C.

In: British Journal of Haematology, Vol. 115, No. 4, 2001, p. 903-909.

Research output: Contribution to journalArticle

Kappelmayer, J. ; Kiss, Attila ; Karászi, Éva ; Veszprémi, Anikó ; Jakó, János ; Kiss, C. / Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias. In: British Journal of Haematology. 2001 ; Vol. 115, No. 4. pp. 903-909.
@article{89308f32b5a7435aa8ab48a18dfa1085,
title = "Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias",
abstract = "Immunophenotyping is considered to be less valuable in the diagnosis of acute myeloid leukaemias (AML) compared with acute lymphoid leukaemias. Here, we present data on the use of quantitative flow cytometry (QFC) of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and three-colour immunophenotyping including CD162 staining in the identification of myeloid precursors in AML. Analysis of normal peripheral blood (n = 20) and normal bone marrow (n = 5) samples and on 20 samples from de novo M1, M2, M4 and M5 AML patients demonstrated that PSGL-1 is differentially expressed on various mature and immature leucocyte subsets. It was found by QFC that neutrophils expressed 26500 ± 4500 and monocytes 47200 ± 9900 copies of PSGL-1 on their surface, whereas AML blasts from M1 and M2 AML patients expressed significantly less PSGL-1 (12 000 ± 5300) than mature neutrophils (P <0.001). In M4 and M5 leukaemias, however, the amount of PSGL-1 on monocytic precursors is displayed in a fairly broad range that is not significantly different from that of mature monocytes (P = 0.084). Using three-colour immunophenotyping PSGL-1-dim staining was co-expressed with CD7 and C34 positivity and PSGL-1 staining intensity on immature myeloid cells paralleled with CD45 expression. This would imply a differential expression of PSGL-1 during myeloid haematopoietic development and suggests that quantification of surface PSGL-1 may aid in differentiating myeloblasts from monoblasts by immunophenotyping in different AML subsets.",
keywords = "Monoblast, Myeloblast, PSGL-1, Quantitative flow cytometry",
author = "J. Kappelmayer and Attila Kiss and {\'E}va Kar{\'a}szi and Anik{\'o} Veszpr{\'e}mi and J{\'a}nos Jak{\'o} and C. Kiss",
year = "2001",
doi = "10.1046/j.1365-2141.2001.03179.x",
language = "English",
volume = "115",
pages = "903--909",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Identification of P-selectin glycoprotein ligand-1 as a useful marker in acute myeloid leukaemias

AU - Kappelmayer, J.

AU - Kiss, Attila

AU - Karászi, Éva

AU - Veszprémi, Anikó

AU - Jakó, János

AU - Kiss, C.

PY - 2001

Y1 - 2001

N2 - Immunophenotyping is considered to be less valuable in the diagnosis of acute myeloid leukaemias (AML) compared with acute lymphoid leukaemias. Here, we present data on the use of quantitative flow cytometry (QFC) of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and three-colour immunophenotyping including CD162 staining in the identification of myeloid precursors in AML. Analysis of normal peripheral blood (n = 20) and normal bone marrow (n = 5) samples and on 20 samples from de novo M1, M2, M4 and M5 AML patients demonstrated that PSGL-1 is differentially expressed on various mature and immature leucocyte subsets. It was found by QFC that neutrophils expressed 26500 ± 4500 and monocytes 47200 ± 9900 copies of PSGL-1 on their surface, whereas AML blasts from M1 and M2 AML patients expressed significantly less PSGL-1 (12 000 ± 5300) than mature neutrophils (P <0.001). In M4 and M5 leukaemias, however, the amount of PSGL-1 on monocytic precursors is displayed in a fairly broad range that is not significantly different from that of mature monocytes (P = 0.084). Using three-colour immunophenotyping PSGL-1-dim staining was co-expressed with CD7 and C34 positivity and PSGL-1 staining intensity on immature myeloid cells paralleled with CD45 expression. This would imply a differential expression of PSGL-1 during myeloid haematopoietic development and suggests that quantification of surface PSGL-1 may aid in differentiating myeloblasts from monoblasts by immunophenotyping in different AML subsets.

AB - Immunophenotyping is considered to be less valuable in the diagnosis of acute myeloid leukaemias (AML) compared with acute lymphoid leukaemias. Here, we present data on the use of quantitative flow cytometry (QFC) of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and three-colour immunophenotyping including CD162 staining in the identification of myeloid precursors in AML. Analysis of normal peripheral blood (n = 20) and normal bone marrow (n = 5) samples and on 20 samples from de novo M1, M2, M4 and M5 AML patients demonstrated that PSGL-1 is differentially expressed on various mature and immature leucocyte subsets. It was found by QFC that neutrophils expressed 26500 ± 4500 and monocytes 47200 ± 9900 copies of PSGL-1 on their surface, whereas AML blasts from M1 and M2 AML patients expressed significantly less PSGL-1 (12 000 ± 5300) than mature neutrophils (P <0.001). In M4 and M5 leukaemias, however, the amount of PSGL-1 on monocytic precursors is displayed in a fairly broad range that is not significantly different from that of mature monocytes (P = 0.084). Using three-colour immunophenotyping PSGL-1-dim staining was co-expressed with CD7 and C34 positivity and PSGL-1 staining intensity on immature myeloid cells paralleled with CD45 expression. This would imply a differential expression of PSGL-1 during myeloid haematopoietic development and suggests that quantification of surface PSGL-1 may aid in differentiating myeloblasts from monoblasts by immunophenotyping in different AML subsets.

KW - Monoblast

KW - Myeloblast

KW - PSGL-1

KW - Quantitative flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=0035676677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035676677&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.03179.x

DO - 10.1046/j.1365-2141.2001.03179.x

M3 - Article

C2 - 11843824

AN - SCOPUS:0035676677

VL - 115

SP - 903

EP - 909

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -